{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T07:18:13Z","timestamp":1790320693996,"version":"4.1.0"},"reference-count":44,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2010,2,1]],"date-time":"2010-02-01T00:00:00Z","timestamp":1264982400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2010,2]]},"DOI":"10.1016\/j.antiviral.2009.11.006","type":"journal-article","created":{"date-parts":[[2009,11,20]],"date-time":"2009-11-20T10:27:35Z","timestamp":1258712855000},"page":"396-402","source":"Crossref","is-referenced-by-count":12,"title":["Human leukocyte antigen alleles and the response to pegylated interferon\/ribavirin therapy in chronic hepatitis C patients"],"prefix":"10.1016","volume":"85","author":[{"given":"Chia-Yen","family":"Dai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wan-Long","family":"Chuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Yen","family":"Hsieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jee-Fu","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-Yun","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei-Yu","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nai-Jen","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zu-Yau","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinn-Cherng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Yuh","family":"Hsieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang-Yen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Lung","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"38","key":"10.1016\/j.antiviral.2009.11.006_bib1","doi-asserted-by":"crossref","first-page":"S104","DOI":"10.1016\/S0168-8278(03)00008-4","article-title":"Management of hepatitis C","volume":"1","author":"Alberti","year":"2003","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2009.11.006_bib2","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0198-8859(98)00010-X","article-title":"Interferon-alpha therapy in HCV hepatitis: HLA phenotype and cirrhosis are independent predictors of clinical outcome","volume":"59","author":"Almarri","year":"1998","journal-title":"Hum. Immunol."},{"key":"10.1016\/j.antiviral.2009.11.006_bib3","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1053\/gast.1997.v113.pm9352872","article-title":"Genes of the major histocompatibility complex class II influence the outcome of hepatitis C virus infection","volume":"113","author":"Alric","year":"1997","journal-title":"Gastroenterology"},{"key":"10.1016\/j.antiviral.2009.11.006_bib4","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/S0198-8859(99)00021-X","article-title":"Study of the association between major histocompatibility complex class II genes and the response to interferon alpha in patients with chronic hepatitis C infection","volume":"60","author":"Alric","year":"1999","journal-title":"Hum. Immunol."},{"key":"10.1016\/j.antiviral.2009.11.006_bib5","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1038\/nature04079","article-title":"Adaptive immune responses in acute and chronic hepatitis C virus infection","volume":"436","author":"Bowen","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.antiviral.2009.11.006_bib6","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1159\/000087271","article-title":"Treatment of chronic hepatitis C in southern Taiwan","volume":"49","author":"Chuang","year":"2006","journal-title":"Intervirology"},{"key":"10.1016\/j.antiviral.2009.11.006_bib7","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.antiviral.2005.04.003","article-title":"Polymorphisms in the interferon-\u03b3 gene at position +874 in patients with chronic hepatitis C treated with high dose interferon-\u03b1 and ribavirin","volume":"67","author":"Dai","year":"2005","journal-title":"Antiviral Res."},{"key":"10.1016\/j.antiviral.2009.11.006_bib8","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1086\/498244","article-title":"Tumor necrosis factor alpha promoter polymorphism at position \u2212308 predicts response to combination therapy in hepatitis C virus infection","volume":"193","author":"Dai","year":"2006","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2009.11.006_bib9","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jhep.2008.03.016","article-title":"Associations between hepatitis C viremia and low serum triglyceride and cholesterol levels: a community-based study","volume":"49","author":"Dai","year":"2008","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2009.11.006_bib10","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.jhep.2008.12.017","article-title":"Insulin resistance predicts response to peginterferon-alpha\/ribavirin combination therapy in chronic hepatitis C patients","volume":"50","author":"Dai","year":"2009","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2009.11.006_bib11","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1053\/jhep.2001.20642","article-title":"HLA class II genes determine the natural variance of hepatitis C viral load","volume":"33","author":"Fanning","year":"2001","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2009.11.006_bib12","doi-asserted-by":"crossref","first-page":"346","DOI":"10.7326\/0003-4819-140-5-200403020-00010","article-title":"Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose","volume":"140","author":"Hadziyannis","year":"2004","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.antiviral.2009.11.006_bib13","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S0168-8278(97)80169-9","article-title":"MHC class II genes influence the susceptibility to chronic active hepatitis C","volume":"27","author":"H\u00f6hler","year":"1997","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2009.11.006_bib14","first-page":"80","article-title":"Hepatitis C virus genotypes, HLA-DRB alleles and their response to interferon-alpha and ribavirin in patients with chronic hepatitis C","volume":"4","author":"Jiao","year":"2005","journal-title":"Hepatobiliary Pancreat. Dis. Int."},{"key":"10.1016\/j.antiviral.2009.11.006_bib15","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/nm0496-405","article-title":"Influence of combinations of human major histocompatibility complex genes on the course of HIV-1 infection","volume":"2","author":"Kaslow","year":"1996","journal-title":"Nat. Med."},{"key":"10.1016\/j.antiviral.2009.11.006_bib16","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1097\/00042737-199810000-00009","article-title":"The effect of HLA alleles on response to interferon therapy in patients with chronic hepatitis C","volume":"10","author":"Kikuchi","year":"1998","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.antiviral.2009.11.006_bib17","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1002\/hep.1840010511","article-title":"Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis","volume":"1","author":"Knodell","year":"1981","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.antiviral.2009.11.006_bib18","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/j.1365-2893.1997.tb00178.x","article-title":"The role of immune responses in the pathogenesis of hepatitis C virus infection","volume":"4","author":"Koziel","year":"1997","journal-title":"J. Viral Hepat."},{"key":"10.1016\/j.antiviral.2009.11.006_bib19","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/S0168-8278(01)00041-1","article-title":"A novel cytotoxic T-cell epitope presented by HLA-A24 molecule in hepatitis C virus infection","volume":"34","author":"Kurokohchi","year":"2001","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2009.11.006_bib20","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1053\/jhep.2002.32672","article-title":"Mechanism of action of ribavirin in the combination treatment of chronic HCV infection","volume":"35","author":"Lau","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2009.11.006_bib21","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1046\/j.1365-2362.1999.00464.x","article-title":"Increased frequency of the HLA-DR15 (B1*15011) allele in German patients with self-limited hepatitis C virus infection","volume":"29","author":"Lechmann","year":"1999","journal-title":"Eur. J. Clin. Invest."},{"key":"10.1016\/j.antiviral.2009.11.006_bib22","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1086\/500952","article-title":"Hepatitis C virus-specific immune responses and quasi-species variability at baseline are associated with nonresponse to antiviral therapy during advanced hepatitis C","volume":"193","author":"Morishima","year":"2006","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2009.11.006_bib23","first-page":"1","volume":"19","author":"NIH Consensus Statement on Management of Hepatitis C","year":"2002","journal-title":"NIH Consens State Sci Statements"},{"key":"10.1016\/j.antiviral.2009.11.006_bib24","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1099\/0022-1317-74-11-2385","article-title":"Characterization of the genomic sequence of type V (or 3a) hepatitis C virus isolates and PCR primers for specific detection","volume":"74","author":"Okamoto","year":"1993","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.antiviral.2009.11.006_bib25","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1136\/bmj.316.7139.1236","article-title":"What's wrong with Bonferroni adjustments","volume":"316","author":"Perneger","year":"1998","journal-title":"BMJ"},{"key":"10.1016\/j.antiviral.2009.11.006_bib26","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1096\/fasebj.12.9.625","article-title":"Influence of host genes on HIV-1 disease progression","volume":"12","author":"Roger","year":"1998","journal-title":"FASEB J."},{"key":"10.1016\/j.antiviral.2009.11.006_bib27","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1111\/j.1572-0241.2003.07537.x","article-title":"HLA class I B44 is associated with sustained response to interferon+ribavirin therapy in patients with chronic hepatitis C","volume":"98","author":"Romero-G\u00f3mez","year":"2003","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.antiviral.2009.11.006_bib28","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/0168-8278(91)90084-O","article-title":"Classification of chronic viral hepatitis: a need for reassessment","volume":"13","author":"Scheuer","year":"1991","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2009.11.006_bib29","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/S0198-8859(96)00257-1","article-title":"HLA gene haplotype frequencies in bone marrow donors worldwide registries","volume":"52","author":"Schipper","year":"1997","journal-title":"Hum. Immunol."},{"key":"10.1016\/j.antiviral.2009.11.006_bib30","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1034\/j.1399-0039.1999.530106.x","article-title":"Distribution of HLA gene and haplotype frequencies in Taiwan: a comparative study among Min-nan, Hakka, Aborigines and Mainland Chinese","volume":"53","author":"Shaw","year":"1999","journal-title":"Tissue Antigens"},{"key":"10.1016\/j.antiviral.2009.11.006_bib31","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1046\/j.1365-2893.1998.00111.x","article-title":"Response to interferon therapy: influence of human leucocyte antigen alleles in patients with chronic hepatitis C","volume":"5","author":"Sim","year":"1998","journal-title":"J. Viral Hepat."},{"key":"10.1016\/j.antiviral.2009.11.006_bib32","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1002\/hep.20119","article-title":"Diagnosis, management, and treatment of hepatitis C","volume":"39","author":"Strader","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2009.11.006_bib33","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/S0168-8278(99)80093-2","article-title":"Ribavirin polarizes human T cell responses towards a Type 1 cytokine profile","volume":"30","author":"Tam","year":"1999","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2009.11.006_bib34","doi-asserted-by":"crossref","first-page":"4792","DOI":"10.1128\/JVI.76.10.4792-4797.2002","article-title":"HLA-Cw*04 and hepatitis C virus persistence","volume":"76","author":"Thio","year":"2002","journal-title":"J. Virol."},{"issue":"2","key":"10.1016\/j.antiviral.2009.11.006_bib35","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1111\/j.1365-2893.1997.tb00187.x","article-title":"Immunogenetics of hepatitis B virus infection","volume":"4","author":"Thomas","year":"1997","journal-title":"J. Viral Hepat."},{"key":"10.1016\/j.antiviral.2009.11.006_bib36","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1016\/S0140-6736(99)91443-5","article-title":"Influence of MHC class II genotype on outcome of infection with hepatitis C virus. The HENCORE group. Hepatitis C European Network for Cooperative Research","volume":"354","author":"Thursz","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.antiviral.2009.11.006_bib37","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/S0198-8859(01)00301-9","article-title":"Genetic link between Asians and native Americans: evidence from HLA genes and haplotypes","volume":"62","author":"Tokunaga","year":"2001","journal-title":"Hum. Immunol."},{"key":"10.1016\/j.antiviral.2009.11.006_bib38","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1086\/375554","article-title":"Human leukocyte antigen class I and II alleles and response to interferon-alpha treatment in Taiwanese patients with chronic hepatitis C virus infection","volume":"188","author":"Yu","year":"2003","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2009.11.006_bib39","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.antiviral.2004.01.002","article-title":"A prospective study on treatment of chronic hepatitis C with tailored and extended interferon-alpha regimens according to pretreatment virological factors","volume":"63","author":"Yu","year":"2004","journal-title":"Antiviral Res."},{"key":"10.1016\/j.antiviral.2009.11.006_bib40","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.trsl.2006.04.006","article-title":"Different viral kinetics between hepatitis C virus genotype 1 and 2 as on-treatment predictors of response to a 24-week course of high-dose interferon-alpha plus ribavirin combination therapy","volume":"148","author":"Yu","year":"2006","journal-title":"Transl. Res."},{"key":"10.1016\/j.antiviral.2009.11.006_bib41","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1136\/gut.2006.102558","article-title":"A randomised study of peginterferon and ribavirin for 16 vs 24 weeks in patients with genotype 2 chronic hepatitis C","volume":"56","author":"Yu","year":"2007","journal-title":"Gut"},{"key":"10.1016\/j.antiviral.2009.11.006_bib42","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1002\/hep.22319","article-title":"Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial","volume":"47","author":"Yu","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2009.11.006_bib43","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1034\/j.1600-0676.2000.020003234.x","article-title":"HLA class II genotypes associated with chronic hepatitis C virus infection and response to alpha-interferon treatment in Poland","volume":"20","author":"Wawrzynowicz-Syczewska","year":"2000","journal-title":"Liver"},{"key":"10.1016\/j.antiviral.2009.11.006_bib44","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/S0168-8278(96)80260-1","article-title":"HLA typing in chronic type B, D and C hepatitis","volume":"24","author":"Zavaglia","year":"1996","journal-title":"J. Hepatol."}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016635420900535X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016635420900535X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T19:53:27Z","timestamp":1558641207000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016635420900535X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,2]]},"references-count":44,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010,2]]}},"alternative-id":["S016635420900535X"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2009.11.006","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2010,2]]}}}